Testosterone therapy for women: what the science says vs. TikTok

What's this video probably claiming?

Based on the hashtags and caption, @activelylizzy is almost certainly making the case that women, specifically those in perimenopause or menopause, are being systematically undertreated with testosterone. The "system is broken" framing is a well-worn trope in the women's hormone space, and it usually comes attached to a few specific claims: that testosterone is routinely ignored by conventional doctors, that it improves energy, libido, mood, and body composition, and that advocacy groups like The Pause Life are filling a gap that mainstream medicine refuses to address. TRT for women is a genuinely contested clinical area, so some of this frustration is warranted. But the gap between legitimate grievance and oversimplified TikTok prescription advice is wide, and without a transcript, we have to flag that the hashtag combo of #hrt and #trt together often signals content that blurs the line between personal testimony and medical recommendation.

What does the science actually show?

The evidence for testosterone in women is real but narrow. A 2019 Global Consensus Statement published in The Journal of Clinical Endocrinology and Metabolism (Davis et al.) reviewed data from over 35 randomized controlled trials and concluded that testosterone has a demonstrated benefit specifically for hypoactive sexual desire disorder (HSDD) in postmenopausal women. That is the one indication with solid RCT backing. The picture gets murkier fast. Studies on testosterone for mood, cognitive function, and fatigue in women are small, short, and inconsistent. A 2021 Cochrane review found no significant effect of testosterone on depressive symptoms or quality of life in menopausal women outside of sexual function. On body composition, a 2014 trial in Menopause (Huang et al.) showed modest lean mass gains at physiological doses, but the clinical significance was limited. The safety data at supraphysiological doses in women is thin, which matters because pellet therapy, popular in direct-to-consumer telehealth, routinely delivers doses well above what those consensus guidelines recommend.

Where does the social media noise diverge from clinical reality?

The biggest divergence is scope creep. Online communities have expanded the clinical indication for female testosterone from HSDD into a catch-all for perimenopause symptoms, brain fog, weight gain, and low motivation. That is not what the RCT evidence supports. A second divergence is delivery method enthusiasm. Pellets are heavily promoted on platforms like TikTok because they are profitable and require infrequent dosing, but the 2019 Davis consensus statement explicitly noted that pellet implants carry a higher risk of supraphysiological levels and adverse effects, and that they are not recommended as a preferred delivery route. Transdermal formulations at lower doses have better safety data. Third, the "your doctor won't tell you this" framing implies suppression of information rather than the more accurate reality: genuine clinical uncertainty combined with an absence of an FDA-approved testosterone product for women in the United States, which itself creates real prescribing hesitancy among physicians who are not wrong to be cautious.

What should you actually know?

If you are a perimenopausal or postmenopausal woman experiencing low libido, testosterone therapy has legitimate evidence behind it and is worth a real conversation with a clinician who can measure your baseline levels and monitor you properly. The Endocrine Society and the International Menopause Society both acknowledge this. What you should be skeptical of is any content that presents testosterone as a broad fix for the full symptom cluster of perimenopause, because estrogen and progesterone have far stronger evidence for most of those symptoms. You should also ask your provider specifically about delivery method and dose monitoring. A 2022 analysis in Climacteric (Panay et al.) noted that many women receiving pellets end up with testosterone levels exceeding male physiological ranges, which carries unknown long-term cardiovascular and oncological risk. Advocacy for better hormonal care for women is legitimate. Advocacy for a specific product category or dosing protocol dressed up as systemic critique is something different.